Bone and cartilage metaplasia in calcific aortic stenosis

Jelena Zorić; Miloš Vuković; Aleksandra Lovrenski; Golub Samardžija; Bojana Andrejić Višnjić; Milana Panjković

doi:10.2298/VSP190505107Z

Jelena Zorić Clinical Center of Vojvodina, Obstetrics and Gynaecology Clinic, Novi Sad, Serbia
Miloš Vuković University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Aleksandra Lovrenski University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Golub Samardžija University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Bojana Andrejić Višnjić University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Milana Panjković University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

DOI: https://doi.org/10.2298/VSP190505107Z

Keywords: aortic value stenosis;, aortic valve calcification;, metaplasia;, risk factors.

Abstract

Background/Aim. Calcification is a frequent change in aortic cusps and the most frequent cause for the occurrence of aortic valve stenosis. Recent studies have shown that the process of aortic calcification is often active and closely related to the formation of bone tissue in calcific aortic stenosis. The aim was to analyze the demographic characteristics of patients with calcific aortic stenosis, the most common symptoms, comorbidities and risk factors, incidence of bone and cartilage metaplasia and its possible association with the present comorbidities, as well as its clinical importance. Methods. We retrospectively analyzed the medical records of 115 patients referred to the University Hospital from January 2013 to December 2015. Results. Calcific aortic stenosis occurred more frequently in males. The average age of patients was 67.3 years. The majority of patients were non-smokers, overweight. The most common clinical symptoms were fatigue, shortness of breath and chest pain. Eighteen (15.6%) patients had no symptoms. Seventeen (14.8%) patients had cartilaginous and osseous metaplasia. Gender, age, smoking and body mass index (BMI) had the same distribution among patients with and without metaplasia. Metaplasia was equally prevalent among patients with moderate, severe and critical aortic stenosis. Conclusion. Age, sex, smoking, BMI and blood pressure values are not risk factors neither for osseous nor for cartilaginous metaplasia.

Author Biographies

Jelena Zorić, Clinical Center of Vojvodina, Obstetrics and Gynaecology Clinic, Novi Sad, Serbia

Obstetrics and Gynaecology Clinic at Clinical Center of Vojvodina

Miloš Vuković, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Center for Imaging Diagnostics, Institute of Oncology of Vojvodina

Aleksandra Lovrenski, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Department of Pathology

Golub Samardžija, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Department of Pathology

Bojana Andrejić Višnjić, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Department of Histology and Embryology

Milana Panjković, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Department of Pathology

References

Rajamannan NM. Bicuspid aortic valve disease: the role of ox-idative stress in Lrp5 bone formation. Cardiovasc Pathol 2011; 20(3): 168-76.

Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI, et al. Calcified rheumatic valve neoangiogene-sis is associated with vascular endothelial growth factor ex-pression and osteoblast-like bone formation. Circula-tion 2005; 111(24): 3296‒301.

Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, et al. Calcific Aortic Valve Disease: Not Simply a Degenerative Process A Review and Agenda for Re-search from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Circulation 2011; 124(16): 1783–91.

Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Do-novan J, Springett M, et al. Human Aortic Valve Calcification Is Associated With an Osteoblast Phenotype. Circulation 2003; 107(17): 2181–4.

Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial Het-erogeneity of Endothelial Phenotypes Correlates With Side-Specific Vulnerability to Calcification in Normal Porcine Aor-tic Valves. Circ Res 2005; 96(7): 792–9.

Paranya G, Vineberg S, Dvorin E, Kaushal S, Roth SJ, Rabkin E, et al. Aortic Valve Endothelial Cells Undergo Transforming Growth Factor-β-Mediated and Non-Transforming Growth Factor-β-Mediated Transdifferentiation in Vitro. Am J Pathol 2001; 159(4): 1335‒43.

Liu AC, Joag VR, Gotlieb AI. The Emerging Role of Valve In-terstitial Cell Phenotypes in Regulating Heart Valve Pathobi-ology. Am J Pathol 2007; 171(5): 1407–18.

Visconti RP, Ebihara Y, LaRue AC, Fleming PA, McQuinn TC, Masuya M, et al. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve in-terstitial cells. Circ Res 2006; 98(5): 690‒6.

Mathieu P, Voisine P, Pépin A, Shetty R, Savard N, Dagenais F. Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity. J Heart Valve Dis 2005; 14(3): 353‒7.

Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcifica-tion: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997; 78(5): 472‒4.

Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29(3): 630‒4.

O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002; 106(17): 2224‒30.

Wakabayashi K, Tsujino T, Naito Y, Ezumi A, Lee-Kawabata M, Nakao S, et al. Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients. Heart Vessels 2011; 26(3): 252‒7.

Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD, et al. A prospective, double-blind, randomized controlled trial of the angiotensin- converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imag-ing 2015; 16(8): 834‒41.

Scatena M, Jackson MF, Speer MY, Leaf EM, Wallingford MC, Giachelli CM. Increased calcific aortic valve disease in response to a diabetogenic, procalcific diet in the LDLr-/-, ApoB100/100 mouse model. Cardiovasc Pathol 2018; 34: 28‒37.

Ing SW, Mohler Iii ER, Putt ME, Torigian D, Leonard MB. Cor-relates of valvular ossification in patients with aortic valve stenosis. Clin Transl Sci 2009; 2(6): 431‒5.

Rattazzi M, Faggin E, Bertacco E, Nardin C, Pagliani L, Pleba-ni M, et al. Warfarin, but not rivaroxaban, promotes the calci-fication of the aortic valve in ApoE−/− mice. 2018; 36(4): e12438.

Lerner RG, Aronow WS, Sekhri A, Palaniswamy C, Ahn C, Singh T, et al. Warfarin use and the risk of valvular calcification. J Thromb Haemost 2009; 7(12): 2023‒7.

Li C, Xu S, Gotlieb AI. The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biolog-ic and physical force feedback loops. Cardiovasc Pathol 2013; 22(1): 1–8.

Sun L, Chandra S, Sucosky P. Ex vivo evidence for the contri-bution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease. PLoS One 2012; 7(10): e48843.

Sun L, Rajamannan NM, Sucosky P. Defining the role of fluid shear stress in the expression of early signaling markers for cal-cific aortic valve disease. PLoS One 2013; 8(12): e84433.

Yang X, Meng X, Su X, Mauchley DC, Ao L, Cleveland JC, et al. Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2. J Thorac Cardiovasc Surg 2009; 138(4): 1008–15.

Alexopoulos A, Bravou V, Peroukides S, Kaklamanis L, Varakis J, Alexopoulos D, et al. Bone regulatory factors NFATc1 and Os-terix in human calcific aortic valves. Int J Cardiol 2010; 139(2): 142–9.

Akahori H, Tsujino T, Naito Y, Yoshida C, Lee-Kawabata M, Ohyanagi M, et al. Intraleaflet haemorrhage as a mechanism of rapid progression of stenosis in bicuspid aortic valve. Int J Cardiol 2013; 167(2): 514–8.

Moreno PR, Astudillo L, Elmariah S, Purushothaman KR, Purushothaman M, Lento PA, et al. Increased macrophage infil-tration and neovascularization in congenital bicuspid aortic valve stenosis. J Thorac Cardiovasc Surg 2011; 142(4): 895–901.

Kanczler JM, Oreffo RO. Osteogenesis and angiogenesis: the po-tential for engineering bone. Eur Cell Mater 2008; 15: 100–14.

Yu Z, Seya K, Daitoku K, Motomura S, Fukuda I, Furukawa K. Tumor necrosis factor-α accelerates the calcification of human aortic valve interstitial cells obtained from patients with cal-cific aortic valve stenosis via the BMP2-Dlx5 pathway. J Pharmacol Exp Ther 2011; 337(1): 16–23.

Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 2009; 135(1): 4–13.

Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J, Pom-erantzeff PM, et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcifi-cation. Arterioscler Thromb Vasc Biol 2008; 28(3): 463–70.

Rajamannan NM. Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS−/− null mice. J Cell Biochem 2012; 113(5): 1623–34.

Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009; 47(6): 828–34.

Ross J Jr, Braunwald E. Aortic stenosis. Circulation 1968; 38(1 Suppl): 61–7.

Rajamannan NM, Gersh B, Bonow RO. Calcific Aortic Stenosis: From bench to the bedside - emerging clinical and cellular concepts. Heart 2003; 89(7): 801–5.

Torre M, Hwang DH, Padera RF, Mitchell RN, VanderLaan PA. Osseous and chondromatous metaplasia in calcific aortic valve stenosis. Cardiovasc Pathol 2016; 25(1): 18‒24.

Steiner I, Kasparová P, Kohout A, Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Vir-chows Arch 2007; 450(6): 653‒7.

Kubota N, Testuz A, Boutten A, Robert T, Codogno I, Duval X, et al. Impact of Fetuin-A on progression of calcific aortic valve stenosis - The COFRASA - GENERAC study. Int J Cardiol 2018; 265: 52‒7.

Greve AM, Bang CN, Boman K, Egstrup K, Forman JL, Kesäniemi A. Effect Modifications of Lipid-Lowering Therapy on Pro-gression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). Am J Cardiol 2018; 121(6): 739‒45.